Affiliation:
1. School of Pharmacy China Pharmaceutical University Nanjing China
2. Galileovasan Offshore and Research and Development Pvt. Ltd. Nagapattinam Tamil Nadu India
3. Pediatric Gastroenterology and Hepatology Research Center, Pediatrics Centre of Excellence Children's Medical Center, Tehran University of Medical Sciences Tehran Iran
4. Student Research Committee, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology Shahid Beheshti University of Medical Sciences Tehran Iran
Abstract
AbstractBackgroundConsidering the conflicting effects of bupropion on parameters related to metabolic syndrome including glucose metabolism and lipid profile, in this meta‐analysis study, we investigated the effects of this drug alone or in combination with naltrexone on glucose metabolism and lipid profile.MethodsScopus, PubMed/Medline, Web of Science and Embase databases were searched using standard keywords to identify all controlled trials investigating effects of bupropion alone and combined with naltrexone on the glucose and lipid profile. Pooled weighted mean difference and 95% confidence intervals were achieved by random‐effects model.ResultsTwelve studies with 5152 participants' were included in this article. The pooled findings showed that bupropion alone or in combination with naltrexone would significantly reduce glucose (weighted mean difference (WMD): −2.25 mg/dL, 95% confidence interval (CI): −4.10, −0.40), insulin (WMD: −4.06 μU/mL, 95% CI: −6.09, −2.03), homeostatic model assessment for insulin resistance (HOMA‐IR) (WMD: −0.58, 95% CI: −0.98, −0.19), triglyceride (TG) (WMD: −11.78 mg/dL, 95% CI: −14.48 to −9.08) and increase high‐density lipoprotein (HDL) (WMD: 2.68 mg/dL, 95% CI: 2.13 to 3.24). A Greater reduction in glucose levels was observed with duration >26 weeks. Dose of bupropion intake ≤360 mg and intervention for more than 26 weeks decreased insulin level significantly. With regard to lipid profile, reduction of triglycerides is more significant with dose of bupropion greater than 360 mg and a shorter intervention length equal to 26 weeks.ConclusionsThe addition of combination therapies such as bupropion and naltrexone to lifestyle modification can significantly improve glucose metabolism and some lipid parameters.
Subject
Clinical Biochemistry,Biochemistry,General Medicine
Reference37 articles.
1. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor;Stahl SM;Prim Care Companion J Clin Psychiatry,2004
2. Sustained‐release naltrexone for opioid dependence;Lobmaier P;Cochrane Database Syst Rev,2008
3. Glucose metabolic dysfunction in neurodegenerative diseases—new mechanistic insights and the potential of hypoxia as a prospective therapy targeting metabolic reprogramming;Han R;Int J Mol Sci,2021
4. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP‐4 inhibitors;Hollander PA;Postgrad Med,2010
5. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2020;Association AD;Diabetes Care,2020